WO2004089947A2 - Neue verbindungen mit antibakterieller aktivität - Google Patents
Neue verbindungen mit antibakterieller aktivität Download PDFInfo
- Publication number
- WO2004089947A2 WO2004089947A2 PCT/EP2004/003306 EP2004003306W WO2004089947A2 WO 2004089947 A2 WO2004089947 A2 WO 2004089947A2 EP 2004003306 W EP2004003306 W EP 2004003306W WO 2004089947 A2 WO2004089947 A2 WO 2004089947A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- groups
- alkyl
- compounds according
- heteroalkyl
- Prior art date
Links
- 0 CCCOc1c(C)cc(C(C*2CCC(COc3c(cc(*C)cc4)c4ccc3)CC2)O*)cc1 Chemical compound CCCOc1c(C)cc(C(C*2CCC(COc3c(cc(*C)cc4)c4ccc3)CC2)O*)cc1 0.000 description 2
- XCRIQFMBACIUDR-UHFFFAOYSA-N COc(ccc1ccn2)cc1c2OCC1CCN(CC(c(cc2N)ccc2O)O)CC1 Chemical compound COc(ccc1ccn2)cc1c2OCC1CCN(CC(c(cc2N)ccc2O)O)CC1 XCRIQFMBACIUDR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present application describes novel compounds with antibacterial activity. These compounds are of interest, inter alia, as inhibitors of topoisomerase IV (topo IV) and of DNA gyrase.
- the present invention relates to compounds of the general formula (I):
- A is an oxygen or a sulfur atom, an NH, an alkylene, an alkenylene, an alkynylene or a heteroalkylene group,
- X 1 , X 2 , X 3 , X 4 and X 5 are independently nitrogen atoms or groups of the formula CH or CR 4 ,
- Cy is a cycloalkylene, a heterocycloalkylene, an arylene or a heteroarylene group.
- R 1 represents a hydrogen atom, a halogen atom, a hydroxy, an amino, a thiol, an alkyl, a heteroalkyl, an alkyloxy, a heteroalkyloxy, a cycloalkyl, a heterocycloalkyl, an alkylcycloalkyl, a heteroalkylcycloalkyl -, is a cycloalkyloxy, an alkylcycloalkyloxy, a heterocycloalkyloxy or a heteroalkylcycloalkyloxy group,
- the radicals R 2 independently of one another are a halogen atom, a hydroxyl, amino, nitro or thiol group, an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, Heterocycloalkyl, aralkyl or a heteroaralkyl radical, or two of the radicals R 2 together form part of an aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aralkyl or heteroaralkyl ring,
- R 3 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or a heteroaralkyl radical,
- R 4 is a halogen atom, a hydroxyl, alkyl, alkenyl, alkynyl or a heteroalkyl group,
- n 0, 1 or 2 and
- n 0, 1 or 2
- alkyl refers to a saturated, straight-chain or branched hydrocarbon group which has 1 to 20 carbon atoms, preferably 1 to 12 carbon atoms, particularly preferably 1 to 6 carbon atoms, e.g. the methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, 2, 2-dimethylbutyl or n-octyl group.
- alkenyl and alkynyl refer to at least partially unsaturated, straight-chain or branched hydrocarbon groups which have 2 to 20 carbon atoms, preferably 2 to 12 carbon atoms, particularly preferably 2 to 6 carbon atoms, e.g. B. the ethenyl, allyl, acetylenyl, propargyl, isoprenyl or hex-2-enyl group.
- Alkenyl groups preferably have one or two (particularly preferably one) double bonds or alkynyl groups have one or two (particularly preferably one) triple bonds.
- alkyl, alkenyl and alkynyl refer to groups in which one or more hydrogen atoms are replaced by a halogen atom (preferably F or Cl), such as, for. B. the 2, 2, 2-trichloroethyl, or the trifluoromethyl group.
- halogen atom preferably F or Cl
- heteroalkyl refers to an alkyl, an alkenyl or an alkynyl group in which one or more (preferably 1, 2 or 3) carbon atoms are replaced by an oxygen, nitrogen, phosphorus, boron, selenium, Silicon or sulfur atom are replaced (preferably oxygen, sulfur or nitrogen).
- heteroalkyl also refers to a carboxylic acid or a group derived from a carboxylic acid, such as. B. acyl, acylalkyl, alkoxycarbonyl, acyloxy, acyloxyalkyl, carboxyalkylamide or alkoxycarbonyloxy.
- heteroalkyl groups are groups of the formulas R a -0-Y a -, RSY a -, R a -N (R b ) -Y-, R-CO-Y a -, R a -0-CO-Y a - R a -C0-0-Y a -, R a -C0-N (R) -Y a -, R a -N (R b ) -C0-Y a -
- R a -0-CO-N (R b ) -Y a -, R a -N (R b ) -C0-0-Y a -, R a -N (R b ) -C0-N (R c ) -Y a - R a -0-CO-0-Y a -, R a -N (R b ) -C ( NR d ) -N (R c ) -Y a -, R a -CS-Y- R a -0-CS-Y a -, R a -CS-0-Y a -, R a -CS-N (R b ) -Y a -, R a -N (R b ) -CS-Y a - R a -0-CS-N (R b ) -Y a -, R a -N (R b ) -CS-Y a -
- heteroalkyl groups are methoxy, trifluoroethoxy, ethoxy, n-propyloxy, iso-propyloxy, tert-butyloxy, methoxymethyl, ethoxymethyl, methoxyethyl, methylamino, ethylamino, dimethylarrtino, diethylamino, iso-propylethylamino, methylaminoethyl, ethylaminomethyl -iso- propylaminoethyl, enol ether, dimethylamino ethyl, dimethylaminoethyl, acetyl, propionyl, butyryloxy, acetyloxy, methoxycarbonyl, ethoxycarbonyl, N-ethyl-N-methylcarbamoyl or N-methylcarbamoyl.
- heteroalkyl groups are nitrile, isonitrile
- cycloalkyl refers to a saturated or partially unsaturated (e.g., cycloalkenyl) cyclic group that has one or more rings (preferred 1 or 2) which form a framework which 3 to
- Cycloalkyl also refers to groups in which one or more hydrogen atoms are replaced by fluorine, chlorine,
- N0 2 groups are replaced, for.
- B. cyclic ketones such. B. cyclohexanone, 2-cyclohexenone or cyclopentanone.
- cycloalkyl groups are the c ⁇ clopro ⁇ yl, cyclobutyl, cyclopentyl, spiro [4,5] decanyl, norborny, cyclohexyl, cyclopentenyl, cyclohexadienyl, decalinyl, bicyclo [4.3.0] nonyl -, tetralin,
- heterocycloalkyl refers to a cycloalkyl group as defined above in which one or more (preferably 1, 2 or 3) ring carbon atoms are represented by an oxygen, nitrogen, silicon, selenium, phosphorus or sulfur atom (preferably oxygen,
- a heterocycloalkyl group preferably has 1 or 2 rings with 3 to 10 (in particular 3, 4, 5, 6 or 7) ring atoms.
- alkylcycloalkyl refers to groups which, in accordance with the above definitions, contain both cycloalkyl and also alkyl, alkenyl or alkynyl groups, e.g. B. alkylcycloalkyl, cycloalkylalkyl, alkylcycloalkenyl, alkenylcycloalkyl and alkynylcycloalkyl groups.
- An alkylcycloalkyl group preferably contains a cycloalkyl group which has one or two ring systems which form a skeleton which contains 3 to 10 (in particular 3, 4, 5, 6 or 7) carbon atoms and one or two alkyl, Alkenyl or alkynyl groups with 1 or 2 to 6 carbon atoms.
- heteroalkylcycloalkyl refers to alkylcycloalkyl groups, as defined above, in which one or more (preferably 1, 2 or 3) carbon atoms are represented by an oxygen, nitrogen, silicon, selenium, phosphorus or sulfur atom (preferably oxygen, sulfur or Nitrogen) are replaced.
- a heteroakylcycloalkyl group preferably has 1 or 2 ring systems with 3 to 10 (in particular 3, 4, 5, 6 or 7) ring atoms and one or two alkyl, alkenyl, alkynyl or heteroalkyl groups with 1 or 2 to 6 carbon atoms.
- Examples of such groups are alkyl heterocycloalkyl, alkyl heterocycloalkenyl, alkenyl heterocycloalkyl, alkynyl heterocycloalkyl, heteroalkylcycloalkyl, heteroalkyl heterocycloalkyl and heteroalkyl heterocylcloalkenyl, the cyclic groups being saturated or mono-, di- or trisaturated.
- aryl or Ar refers to an aromatic group which has one or more rings and is formed by a structure which has 6 to 14 carbon atoms, preferably 6 to 10 (in particular 6) carbon atoms. contains atomic atoms.
- aryl (or Ar) also refers to groups in which one or more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or OH, SH, NH 2 or NO 2 groups. Examples are the phenyl, naphthyl, biphenyl, 2-fluorophenyl, anilinyl, 3-nitrophenyl or 4-hydroxyphenyl group.
- heteroaryl refers to an aromatic group which has one or more rings and is formed by a structure which contains 5 to 14 ring atoms, preferably 5 to 10 (in particular 5 or 6) ring atoms and one or more (preferably 1, 2, 3 or 4) contains oxygen, nitrogen, phosphorus or sulfur ring atoms (preferably 0, S or N).
- heteroaryl also refers to groups in which one or more hydrogen atoms have been replaced by fluorine, chlorine, bromine or iodine atoms or OH, SH, NH 2 or NO 2 groups.
- Examples are 4-pyridyl, 2-imidazolyl, 3-phenylpyrrolyl, thiazolyl, oxazolyl, triazolyl, tetrazolyl, isoxazolyl, indazolyl, indolyl, benzimidazolyl, pyridazinyl, quinolinyl, purinyl -, Carbazolyl, acridinyl, pyrimidyl, 2, 3 '-bifuryl, 3-pyrazolyl and isoquinolinyl groups.
- aralkyl refers to groups which, according to the above definitions, contain both aryl and also alkyl, alkenyl, alkynyl and / or cycloalkyl groups, such as, for. B. arylalkyl, arylalkenyl, arylalkynyl, arylcycloalkyl, arylcycloalkenyl, alkylarylcycloalkyl and alkylarylcycloalkenyl groups.
- aralkyls are toluene, xylene, mesitylene, styrene, benzyl chloride, o-fluorotoluene, 1H-indene, tetralin, Dihydronaphthalenes, indanone, phenylcyclopentyl, cumene, cyclohexylphenyl, fluorene and indane.
- An aralkyl group preferably contains one or two aromatic ring systems (1 or 2 rings) with 6 to 10 carbon atoms and one or two alkyl, alkenyl and / or alkynyl groups with 1 or 2 to 6 carbon atoms and / or a cycloalkyl group with 5 or 6 ring carbon atoms.
- heteroaralkyl refers to an aralkyl group as defined above in which one or more (preferably 1, 2, 3 or 4) carbon atoms are represented by an oxygen, nitrogen, silicon, selenium, phosphorus, boron or Sulfur atom (preferably oxygen, sulfur or nitrogen) are replaced, i. H. to groups which, according to the above definitions, contain both aryl or heteroaryl and also alkyl, alkenyl, alkynyl and / or heteroalkyl and / or cycloalkyl and / or heterocycloalkyl groups.
- a heteroaralkyl group preferably contains one or two aromatic ring systems (1 or 2 rings) with 5 or 6 to 10 carbon atoms and one or two alkyl, alkenyl and / or alkynyl groups with 1 or 2 to 6 carbon atoms and / or a cycloalkyl group with 5 or 6 ring carbon atoms, 1, 2, 3 or 4 of these carbon atoms being replaced by oxygen, sulfur or nitrogen atoms.
- This expression also refers to groups with unsubstituted Ci-C ⁇ alkyl, C 2 -C6 alkenyl, C 2 -C6 alkynyl, Ci-Ce heteroalkyl, C 3 -C ⁇ o cycloalkyl, C 2 -C 9 heterocycloalkyl -, C ⁇ -Cio aryl, -C-C 9 heteroaryl, C 7 -C ⁇ 2 aralkyl or C-Cn heteroaralkyl groups are substituted.
- Compounds of formula (I) can contain one or more centers of chirality due to their substitution.
- the present invention therefore includes both all pure enantiomers and all pure diastereomers, as well as their mixtures in any mixing ratio.
- the present invention also includes all cis / trans isomers of the compounds of the general formula (I) and mixtures thereof.
- the present invention encompasses all tautomeric forms of the compounds of the formula (I).
- Compounds of the formula (I) are further preferred, three, four or five of the groups X 1 , X 2 , X 3 , X 4 and X 5 being CH groups.
- R 1 is preferably a C ⁇ -C 4 alkyloxy or a C 1 -C 4 heteroalkyloxy group, it being possible for one or more hydrogen atoms of these groups to be replaced by fluorine atoms.
- R 1 is particularly preferably a methoxy group.
- R 2 is preferably a hydroxy, a C 1 -C 4 alkyl, C 1 -C 4 heteroalkyl or a Ce-Ci 2 heteroaralkyl group.
- R 3 is more preferably a heteroalkylcycloalkyl or a heteroaralkyl group.
- R 3 is particularly preferably a group of the formula -BY, where B is an alkylene (in particular a C 1 -C 4 -alkylene group), alkenylene, alkynylene or a hetero- alkylene group (in particular a C 1 -C 4 heteroalkylene group) and Y is an aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl or a heteroalkylcycloalkyl group (in particular a heterocycloalkyl or an aryl heterocycloalkyl group ) is.
- B is an alkylene (in particular a C 1 -C 4 -alkylene group), alkenylene, alkynylene or a hetero- alkylene group (in particular a C 1 -C 4 heteroalkylene group)
- Y is an aryl, heteroaryl, aralkyl, heteroaralkyl,
- X 6 , X 7 and X 8 are independently nitrogen atoms or groups of the formula CR 9 , X 9 and X 10 are independently oxygen or sulfur atoms or groups of the formula NR 10 , o is 0, 1 or 2, R 5 , R 6 , R 7 , R 8 and R 9 are independently hydrogen atoms, halogen atoms, hydroxyl, alkyl, alkenyl, alkynyl or heteroalkyl groups and R 10 and R u are independently hydrogen atoms, alkyl, alkenyl, alkynyl or heteroalkyl groups.
- Y particularly preferably has one of the following structures:
- the linker -A- (CH 2 ) - further preferably has a chain length of 2 or 3 atoms.
- R 4 is preferably a fluorine or a chlorine atom or a C 1 -C 4 -alkyloxy or a C 3 -C e - dialkylaminomethyl group, it being possible for one or more hydrogen atoms of these groups to be replaced by fluorine atoms.
- Cy is preferred a cycloalkylene or a heterocycloalkylene group with one or two rings and 4, 5, 6, 7, 8, 9 or 10 ring atoms.
- Cy is particularly preferably a group of the formulas
- U is a nitrogen atom or a group of the formula CH or COH and V is a nitrogen atom or a CH group and p is 0 or 1.
- the substituents can be bound to this group both in an egatory and in an axial manner.
- compositions according to the present invention contain at least one compound of the formula (I) as active ingredient and optionally excipients and / or adjuvants.
- pharmacologically acceptable salts of the compounds of formula (I) are salts of physiologically acceptable mineral acids such as hydrochloric acid, sulfuric acid and phosphoric acid or salts of organic acids such as methanesulfonic acid, p-toluenesulfonic acid, lactic acid, acetic acid, trifluoroacetic acid, citric acid, succinic acid, fumaric acid, maleic acid and salicylic acid.
- Further examples of pharmacologically acceptable salts of the compounds of formula (I) are alkali or alkaline earth metal salts such as.
- Such therapeutically useful agents can be administered in one of the following ways: orally, for example as dragées, coated tablets, pills, semi-solid substances, soft or hard capsules, solutions, emulsions or suspensions; parenterally, eg as an injectable solution; rectally as suppositories; by inhalation, for example as a powder formulation or spray, transdermally or intranasally.
- Combinations with other therapeutic agents can include other antimicrobial and antifungal agents.
- the dose of the biologically active compound according to the invention can vary within wide limits and can be adjusted to individual requirements. Generally a dose of 10 mg to 4000 mg per day is suitable, with a preferred dose being 50 to 3000 mg per day. In suitable cases, the dose can also be below or above the values given above.
- the daily dose can be administered as a single dose or in multiple doses. A typical single dose contains approximately 50 mg, 100 mg, 250 mg, 500 mg, 1 g or 2 g of the active ingredient.
- the BOG group was deprotected as in Example 1 using TFA in DCM.
- Example 7 2- (3- ⁇ [(2,3-dihydrobenzo [1,4] dioxin-6-ylmethyl) amino] methyl ⁇ piperidin-l-yl) -1- (3- methoxy-quinolin-5-yl) ethanol
- the two phases were separated and the organic phase washed with brine (20mL), dried over MgS0 4 and concentrated.
- the crude product was quickly filtered through silica (AcOEt / Hex 1: 1).
- the crude product was taken up in DMF (40 ml) and sodium azide (1.2 g, 18.4 mmol) was added.
- the reaction mixture was stirred at 80 ° C. for 5 hours, concentrated on a rotary evaporator and mixed with ether and water.
- the organic phase was dried over MgS0 4 and concentrated.
- the crude product was purified by chromatography on Si0 2 (hex / EtOAc 4: 1). 2.16 g (9 mmol) could be isolated as an oil.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ543441A NZ543441A (en) | 2003-04-08 | 2004-03-29 | Piperidine derivative compounds having an antibacterial activity |
US10/553,731 US20060205719A1 (en) | 2003-04-08 | 2004-03-29 | Novel compounds having an antibacterial activity |
CA002534891A CA2534891A1 (en) | 2003-04-08 | 2004-03-29 | Novel compounds having an antibacterial activity |
AU2004228147A AU2004228147A1 (en) | 2003-04-08 | 2004-03-29 | Novel compounds having an antibacterial activity |
EP04724014A EP1613624A2 (de) | 2003-04-08 | 2004-03-29 | Neue verbindungen mit antibakterieller aktivität |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2003116081 DE10316081A1 (de) | 2003-04-08 | 2003-04-08 | Neue Verbindungen mit antibakterieller Aktivität |
DE10316081.7 | 2003-04-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004089947A2 true WO2004089947A2 (de) | 2004-10-21 |
WO2004089947A3 WO2004089947A3 (de) | 2005-01-06 |
Family
ID=33016218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/003306 WO2004089947A2 (de) | 2003-04-08 | 2004-03-29 | Neue verbindungen mit antibakterieller aktivität |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060205719A1 (de) |
EP (2) | EP1613624A2 (de) |
AU (1) | AU2004228147A1 (de) |
CA (1) | CA2534891A1 (de) |
DE (1) | DE10316081A1 (de) |
NZ (1) | NZ543441A (de) |
RU (1) | RU2397982C2 (de) |
WO (1) | WO2004089947A2 (de) |
ZA (1) | ZA200508981B (de) |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006032466A2 (en) * | 2004-09-24 | 2006-03-30 | Actelion Pharmaceuticals Ltd | New bicyclic antibiotics |
WO2006087543A1 (en) * | 2005-02-18 | 2006-08-24 | Astrazeneca Ab | Antibacterial piperidine derivatives |
WO2006099884A1 (en) * | 2005-03-24 | 2006-09-28 | Actelion Percurex Ag | Beta-aminoalcohol antibiotics |
US7141564B2 (en) | 2001-05-25 | 2006-11-28 | Smithkline Beecham P.L.C. | Nitrogen-containing bicyclic heterocycles for use as antibacterials |
WO2007014940A2 (en) * | 2005-08-03 | 2007-02-08 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterical agents |
WO2007042325A1 (de) * | 2005-10-13 | 2007-04-19 | Morphochem Aktiengesellschaft für kombinatorische Chemie | 5-chinolinderivate mit antibakterieller aktivität |
US7232832B2 (en) | 2002-11-05 | 2007-06-19 | Smithkline Beecham Corporation | Antibacterial agents |
WO2007105154A2 (en) * | 2006-03-10 | 2007-09-20 | Actelion Pharmaceuticals Ltd | Antibiotic compounds |
WO2007115947A1 (en) | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Pyrrolo-quinoxalinone derivatives as antibacterials |
WO2008003690A1 (en) | 2006-07-03 | 2008-01-10 | Glaxo Group Limited | Azatricyclic compounds and their use |
WO2008009700A1 (en) | 2006-07-20 | 2008-01-24 | Glaxo Group Limited | Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones |
JP2008515796A (ja) * | 2004-10-05 | 2008-05-15 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピペリジン系抗生物質 |
WO2008126024A2 (en) * | 2007-04-11 | 2008-10-23 | Actelion Pharmaceuticals Ltd | Oxazolidinone antibiotic derivatives |
WO2008139288A2 (en) * | 2007-05-09 | 2008-11-20 | Pfizer Inc. | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials |
JP2008545008A (ja) * | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Gpcrアゴニスト |
US7491714B2 (en) | 2002-12-04 | 2009-02-17 | Glaxo Group Limited | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents |
US7498326B2 (en) | 2002-06-26 | 2009-03-03 | Glaxo Group Limited | Compounds |
EP2080761A1 (de) | 2008-01-18 | 2009-07-22 | Glaxo Group Limited | Verbindungen |
US7622481B2 (en) | 2002-06-26 | 2009-11-24 | Glaxo Group Limited | Antibacterial compounds |
US7691850B2 (en) | 2004-06-15 | 2010-04-06 | Glaxo Group Limited | Antibacterial agents |
WO2010043714A1 (en) | 2008-10-17 | 2010-04-22 | Glaxo Group Limited | Tricyclic nitrogen compounds used as antibacterials |
US7709503B2 (en) | 2003-09-13 | 2010-05-04 | Astrazeneca Ab | Pyrrol derivatives with antibacterial activity |
WO2010067332A1 (en) * | 2008-12-12 | 2010-06-17 | Actelion Pharmaceuticals Ltd | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives |
WO2010081874A1 (en) | 2009-01-15 | 2010-07-22 | Glaxo Group Limited | Naphthyridin-2 (1 h)-one compounds useful as antibacterials |
KR20100092965A (ko) * | 2007-12-18 | 2010-08-23 | 액테리온 파마슈티칼 리미티드 | 5-아미노시클릴메틸-옥사졸리딘-2-온 유도체 |
US7820655B2 (en) | 2006-02-15 | 2010-10-26 | Actelion Pharmaceuticals Ltd. | Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives |
US7842810B2 (en) | 2005-03-31 | 2010-11-30 | Janssen Pharmaceutica, Nv | Bicyclic pyrazole compounds as antibacterial agents |
US7875715B2 (en) | 2005-06-16 | 2011-01-25 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
US7999115B2 (en) | 2006-08-30 | 2011-08-16 | Actelion Pharmaceutical Ltd. | Spiro antibiotic derivatives |
JP2011529960A (ja) * | 2008-08-04 | 2011-12-15 | アクテリオン ファーマシューティカルズ リミテッド | 三環式アルキルアミノメチルオキサゾリジノン誘導体 |
US8217029B2 (en) | 2007-04-11 | 2012-07-10 | Actelion Pharmaceuticals Ltd | Oxazolidinone antibiotics |
WO2013021363A1 (en) * | 2011-08-11 | 2013-02-14 | Actelion Pharmaceuticals Ltd | Quinazoline-2,4-dione derivatives |
WO2016027249A1 (en) | 2014-08-22 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection |
WO2017029602A2 (en) | 2015-08-16 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Compounds for use in antibacterial applications |
US10208052B1 (en) | 2017-03-20 | 2019-02-19 | Forma Therapeutics, Inc. | Compositions for activating pyruvate kinase |
US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
US11001588B2 (en) | 2018-09-19 | 2021-05-11 | Forma Therapeutics, Inc. | Activating pyruvate kinase R and mutants thereof |
US11820747B2 (en) | 2021-11-02 | 2023-11-21 | Flare Therapeutics Inc. | PPARG inverse agonists and uses thereof |
US12071440B2 (en) | 2023-03-21 | 2024-08-27 | Novo Nordisk Health Care Ag | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200427688A (en) * | 2002-12-18 | 2004-12-16 | Glaxo Group Ltd | Antibacterial agents |
EP1773831A1 (de) * | 2004-07-08 | 2007-04-18 | Glaxo Group Limited | Antibakterielle mittel |
WO2006046552A1 (ja) * | 2004-10-27 | 2006-05-04 | Toyama Chemical Co., Ltd. | 新規な含窒素複素環化合物およびその塩 |
US20100144717A1 (en) * | 2006-12-15 | 2010-06-10 | Janelle Comita-Prevoir | 2-quinolinone and 2-quinoxalinone-derivatives and their use as antibacterial agents |
AU2008240764C1 (en) * | 2007-04-20 | 2011-10-20 | Glaxo Group Limited | Tricyclic nitrogen containing compounds as antibacterial agents |
CL2008002384A1 (es) * | 2007-08-15 | 2009-07-17 | Glaxo Group Ltd | Compuestos derivados de quinoliniloxipiperidina y pirrolidina, composicion farmaceutica, combinacion farmaceutica, util para el tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio. |
US20100222349A1 (en) * | 2007-10-16 | 2010-09-02 | Glaxo Group Limited | Quinoline derivatives used to treat inflammatory and allergic diseases |
MA41169A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
US10633336B2 (en) | 2014-12-19 | 2020-04-28 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
US10752588B2 (en) | 2014-12-19 | 2020-08-25 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
JP2024524304A (ja) * | 2021-07-08 | 2024-07-05 | へルムホルツ-ツェントルム・フューア・インフェクツィオーンスフォルシュング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 黄色ブドウ球菌のα-溶血素の阻害剤 |
WO2023178035A1 (en) | 2022-03-14 | 2023-09-21 | Slap Pharmaceuticals Llc | Multicyclic compounds |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0264883A2 (de) * | 1986-10-21 | 1988-04-27 | Banyu Pharmaceutical Co., Ltd. | Substituierte Pyridinderivate |
EP0486022A2 (de) * | 1990-11-16 | 1992-05-20 | Eisai Co., Ltd. | Naphthalinderivate |
US5250544A (en) * | 1990-07-10 | 1993-10-05 | Adir Et Compagnie | New piperidine tetrahydropyridine and pyrrolidine compounds |
EP0737670A1 (de) * | 1995-04-14 | 1996-10-16 | Adir Et Compagnie | Tricyclische Amidverbindungen, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen |
US5747502A (en) * | 1989-12-13 | 1998-05-05 | Nippon Kayaku Kabushiki Kaisha | Process for preparing benzo c!phenanthridinium derivatives, novel compounds prepared by said process, and antitumor agents |
WO1999001442A1 (en) * | 1997-07-02 | 1999-01-14 | Zeneca Limited | Triazine derivatives and their use as antibacterial agents |
WO1999048461A2 (en) * | 1998-03-26 | 1999-09-30 | Department Of The Army, U.S. Government | Substituted aromatic compounds for treatment of antibiotic resistant infections |
WO2001010842A2 (en) * | 1999-08-04 | 2001-02-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL265777A (de) * | 1960-06-09 | |||
JPS61200544A (ja) * | 1985-03-04 | 1986-09-05 | Toyo Ink Mfg Co Ltd | 電子写真感光体 |
US5240942A (en) * | 1990-07-10 | 1993-08-31 | Adir Et Compagnie | Piperidine, tetrahydropyridine and pyrrolidine compounds |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
ATE348826T1 (de) | 2000-07-26 | 2007-01-15 | Smithkline Beecham Plc | Aminopiperidin chinoline und ihre azaisosteren analoga mit antibakterieller wirkung |
-
2003
- 2003-04-08 DE DE2003116081 patent/DE10316081A1/de not_active Withdrawn
-
2004
- 2004-03-29 EP EP04724014A patent/EP1613624A2/de not_active Withdrawn
- 2004-03-29 RU RU2005134162/04A patent/RU2397982C2/ru not_active IP Right Cessation
- 2004-03-29 ZA ZA200508981A patent/ZA200508981B/en unknown
- 2004-03-29 AU AU2004228147A patent/AU2004228147A1/en not_active Abandoned
- 2004-03-29 EP EP10013111A patent/EP2298762A2/de not_active Withdrawn
- 2004-03-29 US US10/553,731 patent/US20060205719A1/en not_active Abandoned
- 2004-03-29 WO PCT/EP2004/003306 patent/WO2004089947A2/de active Application Filing
- 2004-03-29 NZ NZ543441A patent/NZ543441A/en not_active IP Right Cessation
- 2004-03-29 CA CA002534891A patent/CA2534891A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0264883A2 (de) * | 1986-10-21 | 1988-04-27 | Banyu Pharmaceutical Co., Ltd. | Substituierte Pyridinderivate |
US5747502A (en) * | 1989-12-13 | 1998-05-05 | Nippon Kayaku Kabushiki Kaisha | Process for preparing benzo c!phenanthridinium derivatives, novel compounds prepared by said process, and antitumor agents |
US5250544A (en) * | 1990-07-10 | 1993-10-05 | Adir Et Compagnie | New piperidine tetrahydropyridine and pyrrolidine compounds |
EP0486022A2 (de) * | 1990-11-16 | 1992-05-20 | Eisai Co., Ltd. | Naphthalinderivate |
EP0737670A1 (de) * | 1995-04-14 | 1996-10-16 | Adir Et Compagnie | Tricyclische Amidverbindungen, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen |
WO1999001442A1 (en) * | 1997-07-02 | 1999-01-14 | Zeneca Limited | Triazine derivatives and their use as antibacterial agents |
WO1999048461A2 (en) * | 1998-03-26 | 1999-09-30 | Department Of The Army, U.S. Government | Substituted aromatic compounds for treatment of antibiotic resistant infections |
WO2001010842A2 (en) * | 1999-08-04 | 2001-02-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
Non-Patent Citations (15)
Title |
---|
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BUDZIKIEWICZ, HERBERT ET AL: "Vincetene, a benzopyrroloisoquinoline alkaloid, from Cynanchum vincetoxicum (L.) Pers. (Asclepiadaceae)" XP002289943 gefunden im STN Database accession no. 1980:22659 & LIEBIGS ANNALEN DER CHEMIE , (8), 1212-31 CODEN: LACHDL; ISSN: 0170-2041, 1979, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FLEISCHHACKER, W. ET AL: "Heterocyclic fused naphthalene systems from thebaine. 1" XP002289942 gefunden im STN Database accession no. 1983:422266 & LIEBIGS ANNALEN DER CHEMIE , (5), 844-51 CODEN: LACHDL; ISSN: 0170-2041, 1983, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FROST, DAVID A. ET AL: "Naturally occurring compounds related to phenalenone. V. Synthetic approaches to structures based on 8,9-dihydro-8,8,9- trimethylphenaleno[1,2-b]furan-7-one" XP002289944 gefunden im STN Database accession no. 1974:36931 & JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999) , (19), 2159-69 CODEN: JCPRB4; ISSN: 0300-922X, 1973, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HARADA, R. ET AL: "Structure of pristimerin, a quinonoid triterpene" XP002289947 gefunden im STN Database accession no. 1963:40179 & TETRAHEDRON LETTERS 603-7 CODEN: TELEAY; ISSN: 0040-4039, 1962, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HARAYAMA, TAKASHI ET AL: "Novel synthesis of naphthobenzazepines from N- bromobenzylnaphthylamines by regioselective C-H activation utilizing the intramolecular coordination of an amine to Pd" XP002289935 gefunden im STN Database accession no. 2003:513206 & SYNLETT , (8), 1141-1144 CODEN: SYNLES; ISSN: 0936-5214, 2003, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IWASAKI, TAMEO ET AL: "Novel Selective PDE IV Inhibitors as Antiasthmatic Agents. Synthesis and Biological Activities of a Series of 1-Aryl-2,3- bis(hydroxymethyl)naphthalene Lignans" XP002289939 gefunden im STN Database accession no. 1996:353917 & JOURNAL OF MEDICINAL CHEMISTRY , 39(14), 2696-2704 CODEN: JMCMAR; ISSN: 0022-2623, 1996, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; JORGENSEN, EUGENE C. ET AL: "Thyroxine analogs. 20. Substituted 1- and 2-naphthyl ethers of 3,5-diiodotyrosine" XP002289945 gefunden im STN Database accession no. 1972:42112 & JOURNAL OF MEDICINAL CHEMISTRY , 14(11), 1023-6 CODEN: JMCMAR; ISSN: 0022-2623, 1971, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KASTURI, TIRUMALAI R. ET AL: "Reactions of tetrahalo-1,2-benzoquinones. III. Reaction of tetrachloro-1,2-benzoquinone with tetralones and naphthols: pathway to the condensates" XP002289946 gefunden im STN Database accession no. 1970:425160 & JOURNAL OF THE CHEMICAL SOCIETY [SECTION] C: ORGANIC , (9), 1257-9 CODEN: JSOOAX; ISSN: 0022-4952, 1970, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MATHE-ALLAINMAT, MONIQUE ET AL: "Synthesis of 2-Amido-2,3-dihydro-1H-phenalene Derivatives as New Conformationally Restricted Ligands for Melatonin Receptors" XP002289938 gefunden im STN Database accession no. 1996:422517 & JOURNAL OF MEDICINAL CHEMISTRY , 39(16), 3089-3095 CODEN: JMCMAR; ISSN: 0022-2623, 1996, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MOEHRLE, H. ET AL: "1,2,3,4-Tetrahydroquinolines as substrates for Mannich compounds" XP002289937 gefunden im STN Database accession no. 1998:474386 & ZEITSCHRIFT FUER NATURFORSCHUNG, B: CHEMICAL SCIENCES , 53(7), 742-752 CODEN: ZNBSEN; ISSN: 0932-0776, 1998, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAGY, PETER I. ET AL: "Theoretical and Experimental Study on Ion-Pair Formation and Partitioning of Organic Salts in Octanol/Water and Dichloromethane/Water Systems" XP002289936 gefunden im STN Database accession no. 2000:428859 & JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , 122(28), 6583-6593 CODEN: JACSAT; ISSN: 0002-7863, 2000, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SMIDRKAL, JAN: "Synthesis of fagaronine" XP002289941 gefunden im STN Database accession no. 1989:614775 & COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS , 53(12), 3184-92 CODEN: CCCCAK; ISSN: 0010-0765, 1988, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; WEI, WAN-GUO ET AL: "A practical procedure for multisubstituted .beta.-naphthols and their derivatives" XP002289934 gefunden im STN Database accession no. 2003:598497 & TETRAHEDRON , 59(34), 6621-6625 CODEN: TETRAB; ISSN: 0040-4020, 2003, * |
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ZHANG, YONGMIN ET AL: "Organic reactions in chiral micelles. 7. The structural effects on the asymmetric oxidation of prochiral sulfides in chiral micelles" XP002289940 gefunden im STN Database accession no. 1991:42166 & CHINESE JOURNAL OF CHEMISTRY , (1), 89-96 CODEN: CJOCEV; ISSN: 1001-604X, 1990, * |
PATENT ABSTRACTS OF JAPAN Bd. 0110, Nr. 29 (P-540), 28. Januar 1987 (1987-01-28) & JP 61 200544 A (TOYO INK MFG CO LTD), 5. September 1986 (1986-09-05) * |
Cited By (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7141564B2 (en) | 2001-05-25 | 2006-11-28 | Smithkline Beecham P.L.C. | Nitrogen-containing bicyclic heterocycles for use as antibacterials |
US7498326B2 (en) | 2002-06-26 | 2009-03-03 | Glaxo Group Limited | Compounds |
US7622481B2 (en) | 2002-06-26 | 2009-11-24 | Glaxo Group Limited | Antibacterial compounds |
US7232832B2 (en) | 2002-11-05 | 2007-06-19 | Smithkline Beecham Corporation | Antibacterial agents |
US7491714B2 (en) | 2002-12-04 | 2009-02-17 | Glaxo Group Limited | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents |
US7709503B2 (en) | 2003-09-13 | 2010-05-04 | Astrazeneca Ab | Pyrrol derivatives with antibacterial activity |
US7691850B2 (en) | 2004-06-15 | 2010-04-06 | Glaxo Group Limited | Antibacterial agents |
WO2006032466A2 (en) * | 2004-09-24 | 2006-03-30 | Actelion Pharmaceuticals Ltd | New bicyclic antibiotics |
WO2006032466A3 (en) * | 2004-09-24 | 2006-12-14 | Actelion Pharmaceuticals Ltd | New bicyclic antibiotics |
JP2008515796A (ja) * | 2004-10-05 | 2008-05-15 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピペリジン系抗生物質 |
JP2007326883A (ja) * | 2005-02-18 | 2007-12-20 | Astrazeneca Ab | 抗菌性のピペリジン誘導体 |
KR101422432B1 (ko) * | 2005-02-18 | 2014-07-22 | 아스트라제네카 아베 | 항균성 피페리딘 유도체 |
WO2006087543A1 (en) * | 2005-02-18 | 2006-08-24 | Astrazeneca Ab | Antibacterial piperidine derivatives |
JP2007326882A (ja) * | 2005-02-18 | 2007-12-20 | Astrazeneca Ab | 抗菌性のピペリジン誘導体 |
US8399489B2 (en) | 2005-02-18 | 2013-03-19 | Astrazeneca Ab | Antibacterial piperdine derivatives |
AU2006215399B2 (en) * | 2005-02-18 | 2010-12-09 | Astrazeneca Ab | Antibacterial piperidine derivatives |
JP2008024715A (ja) * | 2005-02-18 | 2008-02-07 | Astrazeneca Ab | 抗菌性のピペリジン誘導体 |
CN101163693B (zh) * | 2005-02-18 | 2013-03-06 | 阿斯利康(瑞典)有限公司 | 抗菌哌啶衍生物 |
WO2006099884A1 (en) * | 2005-03-24 | 2006-09-28 | Actelion Percurex Ag | Beta-aminoalcohol antibiotics |
US7842810B2 (en) | 2005-03-31 | 2010-11-30 | Janssen Pharmaceutica, Nv | Bicyclic pyrazole compounds as antibacterial agents |
US8232391B2 (en) | 2005-03-31 | 2012-07-31 | Janssen Pharmaceutica Nv | Bicyclic pyrazole compounds as antibacterial agents |
US8242275B2 (en) | 2005-03-31 | 2012-08-14 | Janssen Pharmaceutica Nv | Bicyclic pyrazole compounds as antibacterial agents |
US7875715B2 (en) | 2005-06-16 | 2011-01-25 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
JP2008545008A (ja) * | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Gpcrアゴニスト |
CN101277695B (zh) * | 2005-08-03 | 2011-12-14 | 詹森药业有限公司 | 作为抗菌剂的喹啉衍生物 |
KR101337237B1 (ko) * | 2005-08-03 | 2013-12-06 | 얀센 파마슈티카 엔.브이. | 항균제로서의 퀴놀린 유도체 |
NO341247B1 (no) * | 2005-08-03 | 2017-09-25 | Janssen Pharmaceutica Nv | Kinolinderivater som antibakterielle midler |
WO2007014940A2 (en) * | 2005-08-03 | 2007-02-08 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterical agents |
WO2007014940A3 (en) * | 2005-08-03 | 2007-03-29 | Janssen Pharmaceutica Nv | Quinoline derivatives as antibacterical agents |
TWI381839B (zh) * | 2005-08-03 | 2013-01-11 | Janssen Pharmaceutica Nv | 作為抗菌劑之喹啉衍生物(二) |
US8017606B2 (en) | 2005-08-03 | 2011-09-13 | Janssen Pharmaceutica Nv | Quinoline derivatives as antibacterial agents |
EA014832B1 (ru) * | 2005-08-03 | 2011-02-28 | Янссен Фармацевтика Н.В. | Производные хинолина в качестве антибактериальных средств |
WO2007042325A1 (de) * | 2005-10-13 | 2007-04-19 | Morphochem Aktiengesellschaft für kombinatorische Chemie | 5-chinolinderivate mit antibakterieller aktivität |
US7820655B2 (en) | 2006-02-15 | 2010-10-26 | Actelion Pharmaceuticals Ltd. | Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives |
WO2007105154A3 (en) * | 2006-03-10 | 2007-12-13 | Actelion Pharmaceuticals Ltd | Antibiotic compounds |
JP2009529525A (ja) * | 2006-03-10 | 2009-08-20 | アクテリオン ファーマシューティカルズ リミテッド | 抗菌性の化合物 |
WO2007105154A2 (en) * | 2006-03-10 | 2007-09-20 | Actelion Pharmaceuticals Ltd | Antibiotic compounds |
WO2007115947A1 (en) | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Pyrrolo-quinoxalinone derivatives as antibacterials |
WO2008003690A1 (en) | 2006-07-03 | 2008-01-10 | Glaxo Group Limited | Azatricyclic compounds and their use |
WO2008009700A1 (en) | 2006-07-20 | 2008-01-24 | Glaxo Group Limited | Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones |
US7999115B2 (en) | 2006-08-30 | 2011-08-16 | Actelion Pharmaceutical Ltd. | Spiro antibiotic derivatives |
US8114867B2 (en) | 2007-04-11 | 2012-02-14 | Actelion Pharmaceuticals Ltd | Oxazolidinone antibiotic derivatives |
CN102746297B (zh) * | 2007-04-11 | 2015-08-26 | 埃科特莱茵药品有限公司 | 噁唑烷酮抗生素 |
EP2905283A1 (de) | 2007-04-11 | 2015-08-12 | Actelion Pharmaceuticals Ltd. | Oxazolidinonantibiotika |
EP2915813A1 (de) | 2007-04-11 | 2015-09-09 | Actelion Pharmaceuticals Ltd. | Oxazolidinonantibiotika |
RU2506263C2 (ru) * | 2007-04-11 | 2014-02-10 | Актелион Фармасьютиклз Лтд | Производные оксазолидиновых антибиотиков |
US8217029B2 (en) | 2007-04-11 | 2012-07-10 | Actelion Pharmaceuticals Ltd | Oxazolidinone antibiotics |
WO2008126024A2 (en) * | 2007-04-11 | 2008-10-23 | Actelion Pharmaceuticals Ltd | Oxazolidinone antibiotic derivatives |
CN101657450A (zh) * | 2007-04-11 | 2010-02-24 | 埃科特莱茵药品有限公司 | 噁唑烷酮抗生素衍生物 |
CN102746296B (zh) * | 2007-04-11 | 2015-10-28 | 埃科特莱茵药品有限公司 | 噁唑烷酮抗生素 |
CN102746296A (zh) * | 2007-04-11 | 2012-10-24 | 埃科特莱茵药品有限公司 | 噁唑烷酮抗生素 |
CN102746297A (zh) * | 2007-04-11 | 2012-10-24 | 埃科特莱茵药品有限公司 | 噁唑烷酮抗生素 |
WO2008126024A3 (en) * | 2007-04-11 | 2008-12-04 | Actelion Pharmaceuticals Ltd | Oxazolidinone antibiotic derivatives |
WO2008139288A3 (en) * | 2007-05-09 | 2009-03-26 | Pfizer | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials |
EP2481735A1 (de) * | 2007-05-09 | 2012-08-01 | Pfizer Inc. | Substituierte heterocyclische Derivate und Zusammensetzungen und ihre pharmazeutische Verwendung als antibakterielle Mittel |
WO2008139288A2 (en) * | 2007-05-09 | 2008-11-20 | Pfizer Inc. | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials |
KR101578234B1 (ko) | 2007-12-18 | 2015-12-16 | 액테리온 파마슈티칼 리미티드 | 5-아미노시클릴메틸-옥사졸리딘-2-온 유도체 |
US9505750B2 (en) | 2007-12-18 | 2016-11-29 | Actelion Pharmaceuticals Ltd. | 5-aminocyclylmethyl-oxazolidin-2-one derivatives |
KR20100092965A (ko) * | 2007-12-18 | 2010-08-23 | 액테리온 파마슈티칼 리미티드 | 5-아미노시클릴메틸-옥사졸리딘-2-온 유도체 |
EP2080761A1 (de) | 2008-01-18 | 2009-07-22 | Glaxo Group Limited | Verbindungen |
JP2011529960A (ja) * | 2008-08-04 | 2011-12-15 | アクテリオン ファーマシューティカルズ リミテッド | 三環式アルキルアミノメチルオキサゾリジノン誘導体 |
WO2010043714A1 (en) | 2008-10-17 | 2010-04-22 | Glaxo Group Limited | Tricyclic nitrogen compounds used as antibacterials |
US8211890B2 (en) | 2008-12-12 | 2012-07-03 | Actelion Pharmaceuticals | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives |
WO2010067332A1 (en) * | 2008-12-12 | 2010-06-17 | Actelion Pharmaceuticals Ltd | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives |
WO2010081874A1 (en) | 2009-01-15 | 2010-07-22 | Glaxo Group Limited | Naphthyridin-2 (1 h)-one compounds useful as antibacterials |
CN103732593A (zh) * | 2011-08-11 | 2014-04-16 | 埃科特莱茵药品有限公司 | 喹唑啉-2,4-二酮衍生物 |
US8916573B2 (en) | 2011-08-11 | 2014-12-23 | Actelion Pharmaceuticals Ltd. | Quinazoline-2,4-dione derivatives |
WO2013021363A1 (en) * | 2011-08-11 | 2013-02-14 | Actelion Pharmaceuticals Ltd | Quinazoline-2,4-dione derivatives |
WO2016027249A1 (en) | 2014-08-22 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection |
EP3639824A1 (de) | 2014-08-22 | 2020-04-22 | GlaxoSmithKline Intellectual Property Development Limited | Tricyclische stickstoffhaltige verbindungen zur behandlung einer infektion mit neisseria gonorrhoea |
WO2017029602A2 (en) | 2015-08-16 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Compounds for use in antibacterial applications |
US10472371B2 (en) | 2017-03-20 | 2019-11-12 | Forma Therapeutics, Inc. | Compositions for activating pyruvate kinase |
US10208052B1 (en) | 2017-03-20 | 2019-02-19 | Forma Therapeutics, Inc. | Compositions for activating pyruvate kinase |
US11649242B2 (en) | 2017-03-20 | 2023-05-16 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
US10836771B2 (en) | 2017-03-20 | 2020-11-17 | Forma Therapeutics, Inc. | Compositions for activating pyruvate kinase |
US11396513B2 (en) | 2017-03-20 | 2022-07-26 | Forma Therapeutics, Inc. | Compositions for activating pyruvate kinase |
US11014927B2 (en) | 2017-03-20 | 2021-05-25 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
US11071725B2 (en) | 2018-09-19 | 2021-07-27 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
US11001588B2 (en) | 2018-09-19 | 2021-05-11 | Forma Therapeutics, Inc. | Activating pyruvate kinase R and mutants thereof |
US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
US11844787B2 (en) | 2018-09-19 | 2023-12-19 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
US11980611B2 (en) | 2018-09-19 | 2024-05-14 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
US11820747B2 (en) | 2021-11-02 | 2023-11-21 | Flare Therapeutics Inc. | PPARG inverse agonists and uses thereof |
US12071440B2 (en) | 2023-03-21 | 2024-08-27 | Novo Nordisk Health Care Ag | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
Also Published As
Publication number | Publication date |
---|---|
WO2004089947A3 (de) | 2005-01-06 |
EP2298762A2 (de) | 2011-03-23 |
RU2397982C2 (ru) | 2010-08-27 |
US20060205719A1 (en) | 2006-09-14 |
NZ543441A (en) | 2008-12-24 |
DE10316081A1 (de) | 2004-10-21 |
EP1613624A2 (de) | 2006-01-11 |
ZA200508981B (en) | 2007-03-28 |
RU2005134162A (ru) | 2006-09-10 |
AU2004228147A1 (en) | 2004-10-21 |
CA2534891A1 (en) | 2004-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004089947A2 (de) | Neue verbindungen mit antibakterieller aktivität | |
WO2004035569A2 (de) | Neue verbindungen mit antibakterieller aktivität | |
DE102004041163A1 (de) | Neue Verbindungen mit antibakterieller Aktivität | |
EP1521769B1 (de) | Tubulysinkonjugate | |
EP1943222A1 (de) | 5-chinolinderivate mit antibakterieller aktivität | |
DE60221684T2 (de) | Antibiotika mit doppelwirkung | |
WO2004005327A1 (de) | Neue tubulysinanaloga | |
DE102005019181A1 (de) | Peptid-Deformylase (PDF) Inhibitoren 1 | |
DE102005017116A1 (de) | Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP) | |
EP0019081B1 (de) | Neue Flavonderivate, deren Herstellung, diese neuen und bekannte Flavone als antivirale Wirkstoffe und sie enthaltende pharmazeutische Präparate | |
ZA200502862B (en) | Novel compounds with antibacterial activity | |
EP1660489B1 (de) | Zwischenprodukte für die herstellung von oxazolidinon-chinolon hybriden | |
DE10320453A1 (de) | Neue Bioisostere von Actinonin | |
DE19932314A1 (de) | Benzofuranderivate | |
EP1521750A1 (de) | Neue makrocyclen zur behandlung von krebserkrankungen | |
DE10256405A1 (de) | Neue Verbindungen, die Topoisomerase IV inhibieren | |
WO2004060261A2 (de) | Verbindungen, die faktor viia-aktivtat inhieren | |
DE19909785A1 (de) | Neue, substituierte Isoxazoline | |
DE60212153T2 (de) | Tetrahydropyranderivate und ihre verwendung als therapeutika | |
DE102005026231A1 (de) | Peptid-Deformylase (PDF) Inhibitoren 3 | |
DE60315413T2 (de) | Antimikrobielle dihydrothiazin- und dihydrothiopyranoxazolidinone | |
DE10256976A1 (de) | Hydroxamsäuren als Methionin-Aminopeptidase (MAP) Inhibitoren | |
DE102006028649A1 (de) | Neue Verbindungen mit antibakterieller Aktivität | |
DE102007013812A1 (de) | Neue Inhibitoren van Aspartylproteasen | |
DE10342292A1 (de) | Neue Makrolid Antibiotika |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004724014 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/08981 Country of ref document: ZA Ref document number: 1244/MUMNP/2005 Country of ref document: IN Ref document number: 200508981 Country of ref document: ZA Ref document number: 2004228147 Country of ref document: AU Ref document number: 543441 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005134162 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2004228147 Country of ref document: AU Date of ref document: 20040329 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004228147 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004724014 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10553731 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2534891 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 10553731 Country of ref document: US |